Scarica l'app Stockscreener
2.26
0.88%
-0.02
Dopo l'orario di chiusura:
2.27
0.01
+0.44%
Precedente Chiudi:
$2.28
Aprire:
$2.28
Volume 24 ore:
114.92K
Relative Volume:
0.35
Capitalizzazione di mercato:
$58.29M
Reddito:
-
Utile/perdita netta:
$-94.11M
Rapporto P/E:
-0.376
EPS:
-6.01
Flusso di cassa netto:
$-86.06M
1 W Prestazione:
-12.40%
1M Prestazione:
-7.00%
6M Prestazione:
-52.92%
1 anno Prestazione:
-66.96%
Intervallo 1D:
$2.20
$2.3392
Intervallo di 1 settimana:
$2.11
$2.598
Portata 52W:
$1.78
$10.14
Adverum Biotechnologies Inc Stock (ADVM) Company Profile
Nome
Adverum Biotechnologies Inc
Settore
Industria
Telefono
(650) 649-1004
Indirizzo
100 CARDINAL WAY, REDWOOD CITY, CA
Confronta ADVM con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ADVM
Adverum Biotechnologies Inc
|
2.26 | 58.29M | 0 | -94.11M | -86.06M | -6.01 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Adverum Biotechnologies Inc Stock (ADVM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-06-25 | Iniziato | Oppenheimer | Outperform |
| 2024-04-30 | Iniziato | H.C. Wainwright | Buy |
| 2022-07-07 | Aggiornamento | Truist | Hold → Buy |
| 2021-07-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2021-05-03 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2021-04-29 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2021-04-29 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-04-29 | Downgrade | Truist | Buy → Hold |
| 2020-12-16 | Iniziato | UBS | Neutral |
| 2020-11-12 | Aggiornamento | Raymond James | Underperform → Mkt Perform |
| 2020-06-26 | Downgrade | Raymond James | Mkt Perform → Underperform |
| 2020-05-13 | Iniziato | RBC Capital Mkts | Outperform |
| 2020-05-05 | Aggiornamento | SunTrust | Hold → Buy |
| 2020-04-28 | Iniziato | Goldman | Buy |
| 2020-03-16 | Iniziato | SVB Leerink | Outperform |
| 2020-02-10 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2020-02-10 | Aggiornamento | Chardan Capital Markets | Neutral → Buy |
| 2019-10-15 | Reiterato | Chardan Capital Markets | Neutral |
| 2019-09-13 | Reiterato | Chardan Capital Markets | Neutral |
| 2019-06-14 | Ripresa | Raymond James | Mkt Perform |
| 2018-11-02 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2018-11-02 | Downgrade | SunTrust | Buy → Hold |
| 2018-09-21 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-08-30 | Iniziato | SunTrust | Buy |
| 2018-02-15 | Ripresa | Piper Jaffray | Overweight |
| 2017-10-12 | Iniziato | Raymond James | Outperform |
Mostra tutto
Adverum Biotechnologies Inc Borsa (ADVM) Ultime notizie
Adverum Biotechnologies shareholders approve stock option repricing - Investing.com
Adverum Biotechnologies shareholders approve stock option repricing By Investing.com - Investing.com India
Adverum Biotechnologies’ SWOT analysis: gene therapy stock faces pivotal year - Investing.com Nigeria
Adverum Biotechnologies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Adverum Biotechnologies (NASDAQ:ADVM) versus Metagenomi (NASDAQ:MGX) Head-To-Head Analysis - Defense World
Adverum Awards 14,610 Shares in Stock Options and RSUs to Key New Hires - Stock Titan
Adverum Biotechnologies Reports Q1 2025 Financial Results - TipRanks
Adverum Biotechnologies (ADVM) Sees Price Target Adjustment by RBC Capital | ADVM Stock News - GuruFocus
Adverum Biotechnologies (ADVM) Receives Continued Buy Rating from Chardan Capital | ADVM Stock News - GuruFocus
Adverum Biotechnologies (ADVM) Price Target Reduced by RBC Capit - GuruFocus
Adverum Biotechnologies (ADVM) Rating Reiterated at 'Buy' by HC Wainwright | ADVM Stock News - GuruFocus
RBC Cuts Price Target on Adverum Biotechnologies to $4 From $5, Keeps Sector Perform, Speculative Risk - marketscreener.com
Adverum Biotechnologies: Q1 Earnings Snapshot - CT Insider
Adverum (ADVM) Projects Funding Through Late 2025 | ADVM Stock N - GuruFocus
Adverum Biotechnologies Reports First Quarter 2025 Financial Results and Provides Pipeline Highlights - The Manila Times
Adverum Biotechnologies Reports First Quarter 2025 Financial Results and Provides Pipeline ... - Bluefield Daily Telegraph
Revolutionary One-Time Gene Therapy Shows 3.5-Year Vision Protection in Wet AMD Patients - Stock Titan
Adverum Biotechnologies Inc (ADVM)’s Market Momentum: Closing Strong at 3.23, Down -10.03 - DWinneX
Adverum Biotechnologies’ SWOT analysis: gene therapy firm faces pivotal year - Investing.com Nigeria
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adverum Biotechnologies, Inc.ADVM - PR Newswire
Adverum Biotechnologies' SWOT analysis: gene therapy firm faces pivotal year - Investing.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adverum ... - Bluefield Daily Telegraph
Adverum Biotechnologies Inc expected to post a loss of $1.94 a shareEarnings Preview - TradingView
Adverum Biotechnologies Awards Strategic Stock Options Worth $108,000 to Expand Team - Stock Titan
It makes sense and dollars to buy Adverum Biotechnologies Inc (ADVM) stock - Sete News
Adverum Biotechnologies Inc: Navigating Market Volatility with a 1.79 Debt-to-Equity Ratio - investchronicle.com
Adverum Biotechnologies Inc [ADVM] Investment Guide: What You Need to Know - knoxdaily.com
Should investors be concerned about Adverum Biotechnologies Inc (ADVM)? - uspostnews.com
Gaining Ground: Adverum Biotechnologies Inc (ADVM) Closes Lower at 2.91, Down -2.02 - DWinneX
Press Release Distribution & PR Platform - ACCESS Newswire
Hedge Fund and Insider Trading News: Ken Griffin, Steve Cohen, Scott Bessent, Balyasny Asset Management, Bridgewater Associates, Starboard Value, Maverick Capital, Kodai Capital Management, Antara Capital, Adverum Biotechnologies Inc (ADVM), and - Insider Monkey
Adverum Biotechnologies Insider Bought Shares Worth $1,048,950, According to a Recent SEC Filing - marketscreener.com
Adverum Biotechnologies Insider Buys 350,000 Shares - TradingView
Adverum Biotechnologies Inc (ADVM) is an excellent investment, but the stock is overvalued/undervalued right now - uspostnews.com
Trading Day Triumph: Adverum Biotechnologies Inc (ADVM) Ends at 2.96, a 8.42 Surge/Plunge - DWinneX
Bronstein, Gewirtz & Grossman, LLC Encourages Adverum Biotechnologies, Inc. (ADVM) Stockholders to Inquire about Securities Investigation - markets.businessinsider.com
Truist Removes $40 Price Target on Adverum Biotechnologies, Cites Share Volatility, Keeps Buy Rating - marketscreener.com
Bronstein, Gewirtz & Grossman, LLC Encourages Adverum Biotechnologies, Inc. (ADVM) Investors to Inquire about Securities Investigation - markets.businessinsider.com
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Adverum Biotechnologies, Inc. (ADVM) And Encourages Investors to Reach Out - markets.businessinsider.com
Adverum Biotechnologies (NASDAQ:ADVM) Earns Buy Rating from HC Wainwright - Defense World
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Adverum Biotechnologies, Inc. (ADVM) And Encourages Stockholders to Reach Out - markets.businessinsider.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adverum Biotechnologies, Inc. - GlobeNewswire Inc.
Adverum Biotechnologies Inc Azioni (ADVM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Adverum Biotechnologies Inc Azioni (ADVM) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Seyedkazemi Setareh | CHIEF DEVELOPMENT OFFICER |
May 15 '25 |
Sale |
2.00 |
924 |
1,848 |
13,768 |
| Fischer Laurent | CEO, PRESIDENT AND DIRECTOR |
May 15 '25 |
Sale |
2.00 |
9,126 |
18,252 |
87,488 |
| Leonard Braden Michael | 10% Owner |
Mar 26 '25 |
Buy |
5.04 |
20,407 |
102,841 |
125,207 |
| Leonard Braden Michael | 10% Owner |
Mar 27 '25 |
Buy |
5.19 |
16,593 |
86,089 |
141,800 |
| Leonard Braden Michael | 10% Owner |
Apr 22 '25 |
Buy |
3.00 |
300,000 |
900,000 |
3,057,526 |
| Leonard Braden Michael | 10% Owner |
Apr 23 '25 |
Buy |
2.98 |
50,000 |
148,950 |
191,800 |
| Leonard Braden Michael | 10% Owner |
Mar 31 '25 |
Buy |
4.38 |
19,566 |
85,668 |
2,742,317 |
| Leonard Braden Michael | 10% Owner |
Apr 02 '25 |
Buy |
4.04 |
15,209 |
61,408 |
2,757,526 |
| Leonard Braden Michael | 10% Owner |
Mar 26 '25 |
Buy |
5.04 |
20,407 |
102,841 |
125,207 |
| Leonard Braden Michael | 10% Owner |
Mar 18 '25 |
Buy |
4.69 |
62,341 |
292,418 |
2,667,161 |
1.45%
0.86%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):